Impact of AIDS epidemic in Lampang Province, Thailand (eight years experiences). NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Impact of AIDS epidemic in Lampang Province, Thailand (eight years experiences).

Int Conf AIDS. 1996 Jul 7-12;11(1):144 (abstract no. Mo.C.1513). Unique Identifier : AIDSLINE MED/96921570
Yingseree P; Siraprapasiri T; Wongwichai Y; Wongsakul M; Lampang Provincial Health Office, Ministry of Public Health, Lampang,; Thailand. Fax: (66)(54)227-524.

Abstract: Objective: To describe the extent and impact of AIDS epidemic on morbidity and mortality in Lampang, a province in the northern part of Thailand. Methods: Patients who meet the definition of AIDS and symptomatic HIV are required to be reported to the Provincial Health Office. Death certificates with HIV/AIDS as a cause of death were obtained. Results: The first HIV-positive person and AIDS case were identified in 1988, and 1990, respectively. The number of AIDS and symptomatic HIV cases increased from 2 to 29, 205, 399, 803, and 781 from 1990 to 1995, respectively. Ninety percent of patients contracted HIV through heterosexual transmission. Seventy five percent were age 15-39 years. Male to female sex ratio was 5.1: 1. Pneumocystic carinii pneumonia was the most common opportunistic infection followed by cryptococcosis, and tuberculosis. There were 912 deaths related to HIV/AIDS (113 per 100,000 population) in 1995. AIDS was the leading cause of death in 1995. Eighteen percent of all infant deaths were attributed to AIDS in 1995. Conclusion: AIDS became the leading cause of death in Lampang 8 years after the introduction of HIV.
Keywords: *Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY *HIV Infections/EPIDEMIOLOGYKWDacquiredimmunodeficiencysyndrome/epidemiologyKWDhivinfections/epidemiology
970130
M9715713

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .